scPharmaceuticals Inc. announced it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering its latest furosemide formulation, SCP-111. These new patents will complement four existing patents already owned by the company for the SCP-111 formulation.
The SCP-111 formulation is the subject of a supplemental New Drug Application (sNDA) that the company expects to file in the current quarter. This next-generation delivery system is designed to provide a more convenient option for patients, reducing treatment time significantly.
Management stated that securing additional patent protection is a key strategic achievement that strengthens the company’s intellectual property portfolio. This development supports the advancement of next-generation formulations and reinforces scPharmaceuticals' commitment to delivering transformative outcomes for patients while expanding market opportunities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.